NCT06979141 Dexmedetomidine, Magnesium Sulphate and Lidocaine for Cough Suppression After General Anesthesia
| NCT ID | NCT06979141 |
| Status | Recruiting |
| Phase | Phase 3 |
| Sponsor | Al-Azhar University |
| Condition | Cough |
| Study Type | INTERVENTIONAL |
| Enrollment | 300 participants |
| Start Date | 2025-06-02 |
| Primary Completion | 2026-06-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 3 trials are large pivotal studies comparing the treatment to current standard of care or placebo. Your participation directly contributes to the evidence needed for regulatory approval.
This trial targets 300 participants in total. It began in 2025-06-02 with a primary completion date of 2026-06-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The aim of this prospective randomized controlled double-blinded study is to compare the efficacy of dexmedetomidine, MgSO4 and lidocaine for cough suppression during general anesthetic emergence as regard number and severity.
Eligibility Criteria
Inclusion Criteria: * Aged 21-60 years. * Both genders. * Body mass index \< 30 kg/ m2 * American Society of Anesthesiology (ASA) physical status I-II. * Mallampati score class I or II. * Patients undergoing surgery under general anesthesia. Exclusion Criteria: * Known allergy to study drugs. * History of psychiatric illness. * Patients with major organ diseases. * Pre-existing neurological deficits. * Body mass index \>30 kg/m2. * Active airway infection or history of tracheal and laryngeal surgery. * Lower esophageal sphincter incompetence (and reflux). * Increased intracranial and intraocular pressure. * Use of cough-inducing medications * Pregnant, and lactating women.
Contact & Investigator
Mahmoud T Abd Elhafeez, Specialist.Mcs
PRINCIPAL INVESTIGATOR
mahmoud.talaat750@gmail.com
Frequently Asked Questions
Who can join the NCT06979141 clinical trial?
This trial is open to participants of all sexes, aged 21 Years or older, up to 60 Years, studying Cough. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06979141 trial and what does that mean for participants?
Phase 3 trials are large-scale studies comparing the new treatment to existing standards of care or a placebo. They provide the evidence needed for regulatory approval. This trial targets 300 participants.
Is NCT06979141 currently recruiting?
Yes, NCT06979141 is actively recruiting participants. Contact the research team at Medhathelaly@gmail.com for enrollment information.
Where is the NCT06979141 trial being conducted?
This trial is being conducted at Asyut, Egypt.
Who is sponsoring the NCT06979141 clinical trial?
NCT06979141 is sponsored by Al-Azhar University. The principal investigator is Mahmoud T Abd Elhafeez, Specialist.Mcs at mahmoud.talaat750@gmail.com. The trial plans to enroll 300 participants.